Back to Journals » International Journal of Nanomedicine » Volume 14

Anti-Adhesive And Antiproliferative Synergistic Surface Modification Of Intraocular Lens For Reduced Posterior Capsular Opacification

Authors Han Y, Tang J, Xia J, Wang R, Qin C, Liu S, Zhao X, Chen H, Lin Q

Received 15 May 2019

Accepted for publication 30 October 2019

Published 19 November 2019 Volume 2019:14 Pages 9047—9061

DOI https://doi.org/10.2147/IJN.S215802

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Lei Yang


Video abstract of ID 215802.

Views: 110

Yuemei Han,1,* Junmei Tang,1,* Jiayi Xia,1 Rui Wang,1 Chen Qin,1 Sihao Liu,1 Xia Zhao,1 Hao Chen,1,2 Quankui Lin1,2

1School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, People’s Republic of China; 2Wenzhou Institute of Biomaterials and Engineering, Chinese Academy of Sciences, Wenzhou 32500, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hao Chen
School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Xi Road, Wenzhou 325027, People’s Republic of China
Tel/Fax +86 577 8806 7962
Email chenhao823@mail.eye.ac.cn

Quankui Lin
School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Xi Road, Wenzhou 325027, People’s Republic of China
Tel/Fax +86 577 8806 7962
Email linqk@wmu.edu.cn

Background:
Posterior capsular opacification (PCO) is the main complication after intraocular lens (IOL) implantation in cataract surgery, which is the result of lens epithelial cell (LEC) adhesion, proliferation and migration on the IOL and at the lens capsule interface. Hydrophilic surface modification, such as surface heparinization, decreases the cell adhesion, which has been commercialized and used clinically. However, clinical long-term observation results show no significant difference between the pristine and heparinized IOLs.
Methods: To prevent PCO over the long time span, we modified the IOLs with an antiproliferative drug-loaded hydrophilic coating. The antiproliferative drug doxorubicin (DOX)-incorporated chitosan (CHI) nanoparticle was fabricated by sodium tripolyphosphate (TPP) gelation. Such antiproliferative drug-loaded CHI-TPP-DOX nanoparticles (CTDNP) were used as one of the building blocks to prepare polyelectrolyte multilayer with heparin (HEP) via layer-by-layer assembly, obtaining (HEP/CTDNP)n multilayers. The assembly process was characterized by quartz crystal microbalance with dissipation (QCM-D). The drug release behavior of the coating was investigated by ultra-HPLC (UPLC). In vitro cell experiments were carried out to monitor the effects of multifunctional coatings on cellular adhesion, proliferation and migration. And the intraocular implantation was performed on rabbits to evaluate the in vivo PCO inhibitory effect of such surface-functionalized IOLs.
Results: The positively charged CTDNP was successfully prepared by ionic gelation. The QCM-D results indicate the successful preparation of the (HEP/CTDNP)n multilayer film. Drug release profiles showed that surface-multifunctionalized IOL had drug-sustained release properties. In vitro cell culture results showed significant inhibition of adhesion, proliferation and migration of LECs after surface modification. The in vivo results showed that the IOLs with multifunctionalized surface can effectively reduce the posterior hyperplasia and Soemmering’s ring (SR) formation.
Conclusion: These findings suggested that such multifunctionalized drug-eluting IOLs can effectively reduce the posterior hyperplasia and SR formation when intraocular implantation has a major impact on reducing PCO incidence. Thus they have a great potential in improving patient vision recovery and maintenance.

Keywords: surface modification, intraocular lens, posterior capsular opacification, drug-eluting coating, nanoparticle
 
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]